IBDEI0JA ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8677,0)
 ;;=D68.0^^39^401^213
 ;;^UTILITY(U,$J,358.3,8677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8677,1,3,0)
 ;;=3^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,8677,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,8677,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,8678,0)
 ;;=C88.0^^39^401^214
 ;;^UTILITY(U,$J,358.3,8678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8678,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,8678,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,8678,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,8679,0)
 ;;=C91.02^^39^401^3
 ;;^UTILITY(U,$J,358.3,8679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8679,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,8679,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,8679,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,8680,0)
 ;;=C92.02^^39^401^6
 ;;^UTILITY(U,$J,358.3,8680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8680,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,8680,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,8680,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,8681,0)
 ;;=D09.3^^39^401^50
 ;;^UTILITY(U,$J,358.3,8681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8681,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,8681,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,8681,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,8682,0)
 ;;=C22.0^^39^401^91
 ;;^UTILITY(U,$J,358.3,8682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8682,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,8682,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,8682,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,8683,0)
 ;;=C24.9^^39^401^118
 ;;^UTILITY(U,$J,358.3,8683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8683,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,8683,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,8683,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,8684,0)
 ;;=C50.922^^39^401^142
 ;;^UTILITY(U,$J,358.3,8684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8684,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,8684,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,8684,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,8685,0)
 ;;=C34.91^^39^401^160
 ;;^UTILITY(U,$J,358.3,8685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8685,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,8685,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,8685,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,8686,0)
 ;;=C50.921^^39^401^164
 ;;^UTILITY(U,$J,358.3,8686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8686,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,8686,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,8686,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,8687,0)
 ;;=C90.02^^39^401^176
 ;;^UTILITY(U,$J,358.3,8687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8687,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,8687,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,8687,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,8688,0)
 ;;=D51.9^^39^401^25
 ;;^UTILITY(U,$J,358.3,8688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8688,1,3,0)
 ;;=3^Anemia in Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,8688,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,8688,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,8689,0)
 ;;=C79.51^^39^401^35
 ;;^UTILITY(U,$J,358.3,8689,1,0)
 ;;=^358.31IA^4^2
